European Multidisciplinary Conference on Thoracic Oncology

March 04, 2009

The European Society for Medical Oncology (ESMO), the European Society for Therapeutic Radiology and Oncology (ESTRO), the European Society of Thoracic Surgeons (ESTS) and the European Respiratory Society (ERS) are pleased to announce the first European Multidisciplinary Conference on Thoracic Oncology (EMCTO).

This meeting will provide a comprehensive update and a multidisciplinary perspective of state-of-the-art on the prevention, screening, diagnosis, and treatment of chest tumors, including results of translational research. It will facilitate scientific and clinical exchange, with the aim of promoting an integrated approach to diagnosis, treatment and management of thoracic cancers.

Thoracic cancers are globally recognized as a major cause of mortality. Combating their causes, developing better methods for early detection, advancing research, and improving treatments, require the collaboration of many research and clinical specialties.

Organized in partnership between the European Society for Medical Oncology (ESMO), the European Society for Therapeutic Radiology and Oncology (ESTRO), the European Society of Thoracic Surgeons (ESTS) and the European Respiratory Society (ERS), the conference is designed to provide healthcare professionals with a comprehensive update and a multidisciplinary perspective of state-of-the-art management of patients with thoracic malignancies, including the role of new technologies and the necessary collaboration between various medical specialties.

By bringing together authoritative European partners in thoracic oncology, EMCTO represents an excellent opportunity to promote an integrated approach to diagnosis and treatment of chest tumors and to strengthen European cooperation and scientific exchange .

Meeting highlights: Among the top international experts who have contributed to this multidisciplinary conference: Rolf Stahel, Switzerland; Robert Pirker, Austria; David Gandara, US; Enriqueta Felip, Spain; Giorgio Scagliotti, Italy; Françoise Mornex, France; Paris Kosmidis, Greece; Michael Cullen, UK; Jean-Paul Sculier, Belgium; Cesare Gridelli, Italy; Walter Weder, Switzerland

Meeting venue

The European Multidisciplinary Conference in Thoracic Oncology (EMCTO) will take place at the Palazzo dei Congressi, Lugano.

Services for media representatives

A fully equipped press room will be in operation at the conference with Internet access and telephone lines for registered reporters. You will have access to all the scientific sessions and the possibility to schedule one-on-one interviews with top speakers and presenters of the studies, both in presence and remotely. Please contact the ESMO Communication Dept. at media@esmo.org to already find out about the preliminary timetable or to book a telephone hook up. The conference full program is available at http://www.esmo.org/newsroom/events/

Media registration

To register for the conference as a media representative, please visit http://www.esmo.org/newsroom/events/ and send the Complimentary Media Registration form to the ESMO Communication Department.

Accommodation

For hotel reservation, please visit: http://www.esmo.org/events/lung-2009/book-hotel.html
-end-
Notes to Editors

About the European Society for Medical Oncology (ESMO)

The European Society for Medical Oncology (ESMO) is a non-profit organization which promotes medical oncology and a multidisciplinary approach to cancer treatment.

ESMO is a community of oncology professionals that unites key stakeholders who share the common objective of preventing cancer, fostering a favorable environment for scientific research, and advocating for equal access to high quality cancer treatment. As the leading European professional medical oncology society, ESMO offers state-of-the-art educational and training programs which provide the oncology community with a platform to disseminate the most up-to-date scientific research and information available. ESMO's scientific journal, Annals of Oncology, ranks among the top clinical oncology journals worldwide. ESMO is an authoritative voice in the fight against cancer and offers consultative expertise to oncology organizations and European authorities on important issues related to cancer research, prevention, diagnosis, treatment and cure.

Contacts:
For media inquiries, please contact:
ESMO Press Office
Tel. +41 91 973 19 07
Fax +41 91 973 19 93
E-mail media@esmo.org

Communication Department
European Society for Medical Oncology (ESMO)
Via L. Taddei 4
CH-6962 Viganello-Lugano
Switzerland

European Society for Medical Oncology

Related Oncology Articles from Brightsurf:

Study reveals impact of COVID-19 on oncology staff and their work
A study presented at the NCRI Virtual Showcase reports the results of a survey of oncology staff on their management of patients, their wellbeing and whether they felt valued during the first wave of the COVID-19 pandemic.

Study of COVID-19 levels in oncology staff suggests need for more extensive testing
A study of oncology staff carried out immediately after the spring peak of the COVID-19 pandemic in the UK indicates that many had been infected with the coronavirus as they tested positive for COVID-19 antibodies.

Troubled independent oncology practices in COVID-19 era
The financial risks and challenges for independent oncology practices in the COVID-19 era and possible solutions to promote their stability and survival are discussed in this Viewpoint.

FDA support for oncology drug development during COVID-19
This Viewpoint from the U.S. Food and Drug Administration puts into context recent guidance on clinical trials during COVID-19 for oncology and shares insight regarding regulatory challenges and lessons learned.

Novel immune-oncology approach for potential cancer treatment
A research collaboration between Monash University and Lava Therapeutics details a novel immune-oncology approach for the potential treatment of cancer.

ModGraProDep: Artificial intelligence and probabilistic modelling in clinical oncology
Improving the prediction of survival indicators in patients with breast cancer using tools from artificial intelligence and probabilistic modelling is the aim of ModGraProDep, an innovative system presented in a study led by Ramon Clèries, lecturer at the Department of Clinical Sciences of the Faculty of Medicine and Health Sciences of the University of Barcelona and member of the Oncology Master Plan/ICO-IDIBELL.

Better outcomes, lower cost in first-ever oncology hospital at home evaluation
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) presented the first outcomes evaluation of an adult oncology hospital-at-home program today at the 2020 American Society of Clinical Oncology (ASCO) annual meeting.

Hippocampal avoidance during WBRT reduces risks on NRG Oncology trial
Results from the NRG Oncology clinical study NRG-CC001 concluded that lowering radiotherapy dose to hippocampal stem cells improves cognitive and patient-reported outcomes for patients with brain metastases.

Dozens of non-oncology drugs can kill cancer cells
Researchers tested approximately 4,518 drug compounds on 578 human cancer cell lines and found nearly 50 that have previously unrecognized anti-cancer activity.

10-year results of NRG Oncology/NSABP B-42 trial
In the updated results from NRG Oncology/NSABP B-42 trial through 10 years of observation, extending letrozole therapy for additional five years after five years of adjuvant endocrine therapy resulted in a statistically significant improvement in the 10-year disease-free survival (DFS) of postmenopausal women with hormone-receptor-positive breast cancer.

Read More: Oncology News and Oncology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.